Augmentin 625 vs Moxikind-CV 625: Comparison, Efficacy & Generic Savings
Compare Augmentin 625 Duo (GSK) and Moxikind-CV 625 (Mankind): Amoxicillin + Clavulanic Acid active salts, respiratory infection cure rates, and price.
Augmentin 625 Duo (GSK) and Moxikind-CV 625 (Mankind Pharma) contain the identical active formulation: Amoxicillin 500mg + Clavulanic Acid 125mg. Both overcome beta-lactamase bacterial resistance for severe respiratory, sinus, ear, and dental infections. Both have identical therapeutic efficacy and should be taken at the start of a meal.
1. Active Formula Bioequivalence
Both brands utilize the gold-standard 4:1 ratio of Amoxicillin to Clavulanic acid (500mg:125mg). Potassium clavulanate inactivates bacterial beta-lactamase enzymes, restoring amoxicillin's broad-spectrum killing power.
2. Gastrointestinal Safety & Probiotics
Both brands can cause loose stools due to clavulanic acid. Taking your dose with the first bite of a meal and co-prescribing a probiotic (like Darolac spaced 2 hours apart) minimizes stomach upset.
3. Price Comparison & Jan Aushadhi Savings
Branded Augmentin 625 costs ~₹220 for 10 tablets. Moxikind-CV 625 costs ~₹180 for 10 tablets. Generic Amoxicillin + Clavulanate 625mg at Jan Aushadhi costs just ₹58.00 (74% savings).
Top 8 Essential Indian Medicines: Branded MRP vs. Jan Aushadhi Generic Comparison
Compare average Indian retail MRP of top branded formulations against government-certified PMBJP Jan Aushadhi bioequivalent generic prices and active salts. Verified against official PMBJP formularies, NPPA price caps, and CDSCO regulatory registries.
| Brand Name | Leading Manufacturer | Active Salt Formulation (IP) | Branded MRP | Jan Aushadhi Price | Savings % |
|---|---|---|---|---|---|
| Augmentin 625 Duo | GlaxoSmithKline Pharmaceuticals | Amoxicillin Trihydrate 500mg + Potassium Clavulanate 125mg IP | ₹220.00 | ₹58.00 | 74% |
| Dolo 650 | Micro Labs Ltd | Paracetamol (Acetaminophen) 650mg IP | ₹34.00 | ₹5.50 | 84% |
| Pantocid 40 | Sun Pharmaceutical Industries | Pantoprazole Sodium 40mg IP (Gastro-resistant) | ₹155.00 | ₹8.00 | 95% |
| Azithral 500 | Alembic Pharmaceuticals | Azithromycin Dihydrate 500mg IP | ₹132.00 | ₹24.00 | 82% |
| Glycomet 500 | USV Private Limited | Metformin Hydrochloride 500mg IP | ₹24.00 | ₹4.50 | 81% |
| Shelcal 500 | Torrent Pharmaceuticals | Elemental Calcium 500mg + Cholecalciferol (Vit D3) 250 IU IP | ₹134.00 | ₹16.00 | 88% |
| Telma 40 | Glenmark Pharmaceuticals | Telmisartan 40mg IP | ₹92.00 | ₹7.50 | 92% |
| Montair-LC | Cipla Ltd | Montelukast Sodium 10mg + Levocetirizine Dihydrochloride 5mg IP | ₹210.00 | ₹18.00 | 91% |
| Combined 8-Drug Essential Therapy Basket Total: | ₹1,001.00 | ₹141.00 | 85.9% Net Savings | ||
Frequently Asked Questions (Clinical & Regulatory)
Q1: Is Moxikind-CV 625 as effective as original Augmentin 625?
Yes, both comply with Indian Pharmacopoeia monographs and deliver identical clinical recovery rates.
Q2: Can I cut an Augmentin or Moxikind-CV tablet in half?
Both have moisture-sensitive clavulanic acid. If cut, swallow both halves immediately, as exposed clavulanate degrades rapidly in humid air.
Q3: How does the CDSCO define bioequivalence when comparing two pharmaceutical formulations?
Bioequivalence is confirmed when two pharmaceutical products contain identical active therapeutic moieties and show no statistically significant difference in Cmax and AUC under single-dose fasting and fed pharmacokinetic studies within the 80% to 125% confidence interval.
Q4: When comparing two drugs in the same clinical class, what determines superior therapeutic choice?
Therapeutic selection depends on receptor selectivity, onset speed, elimination half-life, clearance pathway (hepatic CYP450 vs renal excretion), drug interaction liability, and clinical trial evidence regarding organ-specific outcomes.
Q5: Can patients interchange two bioequivalent branded formulations without loss of efficacy?
Yes. Formulations produced under Schedule M Good Manufacturing Practices containing identical active pharmaceutical salts and dissolution profiles can be interchanged safely under pharmacist guidance.
This clinical guide is authored and reviewed in accordance with the regulatory standards of the Indian Pharmacopoeia (IP), Central Drugs Standard Control Organization (CDSCO) drug schedules, and Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) bioequivalence guidelines. All therapeutic recommendations and drug interaction warnings are cross-referenced with official statutory publications.
Under India's Digital Personal Data Protection (DPDP) Act, 2023, MediMatch AI functions as a data fiduciary committed to zero retention of private health identifiers. Browsing educational guides, reviewing active salt monographs, and executing search queries occur without tracking or commercial profiling. All client interactions with prescription readers or lab decoders execute ephemerally in volatile memory with zero server-side storage of protected health information (PHI). For inquiries regarding data fiduciary obligations, contact our Data Protection Officer at privacy@medimatchai.in.